Consolidation and technology are both reshaping how drugs move from clinical development into commercial reach, with one deal betting on scale and another betting on artificial intelligence.

McKesson acquires Precision Medicine Group

McKesson Corporation signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.¹

Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment.¹ Precision Medicine Group supports next-generation approaches to drug development and commercialization, giving biotechnology and pharmaceutical companies integrated services and technology-enabled products that span biomarker intelligence, lab services, a global clinical research organization, market access consulting and commercialization support.¹

"This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to providing patients with access to the highest quality of care," said Brian Tyler, chair and chief executive officer of McKesson. "Precision Medicine Group brings complementary capabilities that will enhance our clinical research and commercialization services, strengthen clinical trial execution, and broaden our clinical service offerings."

"Joining McKesson provides a compelling opportunity to extend the impact of our clinical and commercial expertise for the benefit of our customers, partners and patients they serve," said Margaret Keegan, chief executive officer of Precision Medicine Group. "Together, we will bring a broader set of capabilities to biopharma companies, supporting them through the development and commercialization process. We are excited to join McKesson and advance our shared commitment to enabling innovation and improving patient access."

Lundbeck partners with Eversana to scale AI-powered commercialization

Lundbeck entered a strategic partnership with Eversana, a global provider of commercial services to the life sciences industry, to advance AI-powered commercialization across Lundbeck's U.S. commercial organization.

The collaboration broadens Lundbeck's use of Eversana's AI Agency platform and related commercialization capabilities, creating a scalable framework for accelerating strategy development, content creation, omnichannel engagement and commercial execution.² The partnership supports Lundbeck's Focused Innovator strategy and its ambition to build what the companies describe as bionic capabilities, pairing human expertise with artificial intelligence to achieve results neither can deliver alone.² It follows an earlier deployment of Eversana's AI-powered capabilities in support of Lundbeck's commercialization activities, through which the companies introduced AI-driven workflows to accelerate strategic planning, content development and commercial execution while maintaining rigorous medical, legal and regulatory review processes.²

"At Lundbeck, building bionic capabilities is an important part of how we are advancing our Focused Innovator strategy," said Tom Gibbs, executive vice president and president of Lundbeck U.S. "Our ambition is to bring human expertise and artificial intelligence together to strengthen how we think, decide and execute across our business. Building on the progress we have made with Eversana, our expanded collaboration will help us scale bionic capabilities responsibly across our commercial organization, improve the speed and quality of execution and ultimately, help us deliver greater value to our customers and patients while maintaining the high standards that define our business."

Under the expanded partnership, Lundbeck is expected to scale AI-enabled commercialization capabilities across marketing, medical communications, market access and media operations, with the companies also exploring additional use cases to enhance operational performance.

Launched in 2025 and developed in collaboration with Google Cloud, Eversana's AI Agency is an end-to-end AI-powered commercialization platform built specifically for life sciences, combining agentic AI, advanced automation and human expertise to accelerate the development of strategy, content and omnichannel engagement while supporting the compliance and governance requirements unique to the pharmaceutical industry.

"The future of commercialization will belong to organizations that successfully combine human expertise with AI-driven execution," said Mark Thierer, chief executive officer of Eversana. "Lundbeck is advancing innovation and actively implementing new ways of working. Together, we are creating a model that pairs the power of artificial intelligence with deep life sciences expertise to help commercial teams move faster, operate more efficiently and deliver greater impact."

Sources

1. McKesson Signs Agreement to Acquire Precision Medicine Group, LLC McKesson Corporation August 25, 2026, https://www.businesswire.com/news/home/20260824526382/en/McKesson-Signs-Agreement-to-Acquire-Precision-Medicine-Group-LLC
2. Lundbeck and Eversana Announce Strategic Partnership to Advance AI-Powered Commercialization Eversana August 25, 2026, https://www.prnewswire.com/news-releases/lundbeck-and-eversana-announce-strategic-partnership-to-advance-ai-powered-commercialization-302858538.html